Contact Us

The choice depends on whether you are studying ALOX12B (12R-lipoxygenase, 12R-LOX)'s role in epidermal lipid biology or modeling autosomal recessive congenital ichthyosis (ARCI). The Knockout line is the standard tool for asking whether ALOX12B is required for these processes — ALOX12B catalyzes the conversion of arachidonic acid (or its ester forms in the ω-3 hydroxyceramide pathway) to 12R-HPETE; in epidermal lipid metabolism, ALOX12B works sequentially with ALOXE3 to generate hepoxilin A3 and other epidermal lipid mediators essential for skin barrier formation. Overexpression is useful for studying ALOX12B gain-of-function effects. For skin biology research, the EDITGENE ALOX12B Knockout in HEK293 is highly informative — ALOX12B biallelic loss-of-function mutations cause ⭐ autosomal recessive congenital ichthyosis (ARCI, particularly non-bullous congenital ichthyosiform erythroderma form). This product complements the parallel ALOXE3 Knockout in HEK293 (also available) for studying the ALOX12B-ALOXE3 epidermal lipoxygenase pathway. Rescue with wild-type or catalytically-dead ALOX12B enables structure-function studies. The knockout is valuable for studying epidermal lipid biology, skin barrier formation, and ichthyosis disease mechanisms.

Yes. ALOX12B rescue experiments are well-established for epidermal lipid research: • Construct design: use a codon-modified ALOX12B sequence with a small C-terminal tag (FLAG, HA). ALOX12B has the canonical lipoxygenase architecture with active site iron — preserve all elements. • Catalytically-dead rescue: iron-binding histidine mutations abolish 12R-lipoxygenase activity. • ARCI patient mutation rescue: patient-derived ALOX12B mutations enable disease modeling. • Functional readout: rescue should restore 12R-HPETE synthesis from arachidonic acid substrate. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying ALOX5AP (5-lipoxygenase-activating protein, FLAP)'s role as the essential co-factor for ALOX5/5-lipoxygenase activation or modeling leukotriene biology. The Knockout line is the standard tool for asking whether FLAP is required for these processes — FLAP is a membrane-embedded protein at the nuclear envelope that scaffolds arachidonic acid delivery to ALOX5/5-LOX for leukotriene A4 (LTA4) synthesis; LTA4 is then converted to LTB4 (potent neutrophil chemoattractant) or cysteinyl leukotrienes (LTC4, LTD4, LTE4 — bronchoconstrictors in asthma). Overexpression is useful for studying FLAP gain-of-function effects. For leukotriene biology research, the EDITGENE ALOX5AP/FLAP Knockout in HEK293 is uniquely valuable — FLAP KO completely abolishes leukotriene synthesis. This product complements the parallel ALOX5 Knockout in HEK293 (also available) for systematic 5-LOX pathway dissection. Rescue with wild-type FLAP is the standard specificity control. The knockout is a critical specificity tool for ⭐ MK-886 (classical FLAP inhibitor), fiboflapon (GSK2190915, anti-asthma FLAP inhibitor in clinical development), and emerging FLAP-targeted approaches in asthma, atherosclerosis, and emerging inflammatory disease therapeutics.

Yes. FLAP rescue experiments require attention to nuclear envelope membrane architecture: • Construct design: use a codon-modified ALOX5AP sequence with a small intracellular tag — FLAP is a small (~18 kDa) integral membrane protein with multiple transmembrane domains; small tags preserve membrane topology. • Nuclear envelope localization: confirm nuclear envelope/perinuclear localization by appropriate markers. • AA-binding-deficient rescue: AA-binding-pocket mutations affect 5-LOX activation. • Functional readout: rescue should restore A23187-induced leukotriene synthesis in 5-LOX-expressing cells. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on the experimental question. API5 (apoptosis inhibitor 5, AAC-11) is a less-characterized factor with reported anti-apoptotic functions and emerging functions in cancer. The Knockout line is appropriate for asking whether API5 is required for predicted activities — API5 has been characterized as an anti-apoptotic factor regulated by serum, with reported binding to FGF2 and Acinus; API5 overexpression has been reported in cancers and correlates with chemotherapy resistance. Overexpression is useful for studying API5 gain-of-function effects. For cancer biology research, the EDITGENE API5 Knockout in HEK293 provides a clean genetic background for characterizing API5-specific functions. Rescue with wild-type API5 is the standard specificity control. The knockout is valuable for studying API5-mediated apoptosis suppression, chemotherapy resistance mechanisms, and emerging API5-related cancer biology.

Yes. API5 rescue experiments require attention to less-characterized protein architecture: • Construct design: use a codon-modified API5 sequence with a small C-terminal tag (FLAG, HA). API5 has leucine zipper-like domain — preserve protein integrity. • Discovery-oriented rescue: parallel wild-type rescue during phenotypic characterization distinguishes API5-dependent phenotypes. • Functional readout: rescue should restore API5-dependent apoptosis suppression. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying ARFGEF1 (BIG1)'s role as an Arf GTPase guanine nucleotide exchange factor or modeling its functions in Golgi trafficking. The Knockout line is the standard tool for asking whether ARFGEF1 is required for these processes — ARFGEF1/BIG1 is a Sec7-domain Arf GEF that activates Arf1/Arf3 GTPases at the trans-Golgi network for COP-I-independent vesicle formation; ARFGEF1 is closely related to ARFGEF2/BIG2; both are inhibited by ⭐ brefeldin A (the classical fungal toxin disrupting Golgi structure). Overexpression is useful for studying ARFGEF1 gain-of-function effects. Important consideration: ARFGEF1 and ARFGEF2 share substantial substrate scope — single ARFGEF1 knockout may show modest phenotypes if ARFGEF2 compensates. Rescue with wild-type or catalytically-dead (E794K Sec7 domain glutamate finger) ARFGEF1 is the standard specificity control. The knockout is a critical specificity tool for brefeldin A research (BFA classically inhibits ARFGEF1/2; selective compounds AMF-26 and others are in development) and Golgi trafficking studies.

Yes. ARFGEF1 rescue experiments are well-established for Arf GEF research: • Construct design: use a codon-modified ARFGEF1 sequence with a small C-terminal tag (FLAG, HA). ARFGEF1 has DCB, HUS, Sec7 (catalytic), HDS1-3 domains — preserve all elements. • Catalytically-dead rescue: E794K mutation in the Sec7 domain catalytic glutamate finger abolishes Arf-GEF activity. • Brefeldin A-resistant rescue: F190Y mutation in the Sec7 domain confers BFA resistance, enabling on-target BFA validation. • Functional readout: rescue should restore Arf-GTP loading and Golgi structure. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying AMBRA1's recently characterized role as a Cyclin D1 ubiquitin ligase substrate receptor or modeling autophagy and emerging cancer applications. The Knockout line is the standard tool for asking whether AMBRA1 is required for these processes — AMBRA1 was originally characterized as a Beclin-1-interacting autophagy regulator; landmark 2021 studies (three concurrent Nature papers: Maiani et al., Simoneschi et al., Chaikovsky et al.) identified AMBRA1 as the long-sought Cyclin D1 substrate receptor of a Cullin-4 E3 ligase (CRL4^AMBRA1) that targets D-type cyclins for degradation; AMBRA1 is therefore a tumor suppressor restraining D-cyclin-CDK4/6 activity. Overexpression is useful for studying AMBRA1 gain-of-function effects. For cancer biology research, the EDITGENE AMBRA1 Knockout in HEK293 is uniquely valuable — AMBRA1 is one of the most important newly characterized cancer drug targets, with potential to extend CDK4/6 inhibitor sensitivity through preventing D-cyclin degradation. Rescue with wild-type AMBRA1 enables structure-function studies of both the Cyclin D1-degrading and autophagy-regulating functions. The knockout is valuable for studying Cullin-4 substrate receptor biology, D-cyclin regulation, CDK4/6 inhibitor sensitivity, and emerging AMBRA1-targeted approaches — this is one of the most clinically promising recent discoveries in cell cycle biology.

Yes. AMBRA1 rescue experiments are uniquely powerful for the dual-function biology: • Construct design: use a codon-modified AMBRA1 sequence with a small C-terminal tag (FLAG, HA). AMBRA1 has multiple WD40 repeats and DDB1-binding region — preserve all elements. • Cyclin D1-binding-deficient rescue: substrate-binding region mutations affect D-cyclin recognition. • DDB1-binding-deficient rescue: DDB1-binding region mutations affect CRL4 complex assembly. • Beclin-1-binding rescue: Beclin-1-interaction region mutations separate autophagy from Cyclin D1-ligase functions. • Functional readout: rescue should restore D-cyclin degradation kinetics and autophagy initiation. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation for systematic AMBRA1 functional dissection.

The choice depends on whether you are studying ALOXE3 (epidermal-type lipoxygenase 3, eLOX-3)'s role as a hepoxilin-generating epidermal lipoxygenase or modeling autosomal recessive congenital ichthyosis (ARCI). The Knockout line is the standard tool for asking whether ALOXE3 is required for these processes — ALOXE3 is an atypical lipoxygenase that lacks dioxygenase activity but converts 12R-HPETE (the product of ALOX12B) into hepoxilin A3 (8R-hydroxy-11R,12R-epoxy-eicosatrienoic acid) and related epidermal lipid signaling molecules essential for proper skin barrier formation. Overexpression is useful for studying ALOXE3 gain-of-function effects. For skin biology research, the EDITGENE ALOXE3 Knockout in HEK293 is highly relevant — ALOXE3 biallelic loss-of-function mutations cause ⭐ autosomal recessive congenital ichthyosis (ARCI), a severe skin barrier disorder. This product complements the parallel ALOX12B Knockout in HEK293 (also available) for studying the ALOX12B-ALOXE3 epidermal lipoxygenase pathway. Rescue with wild-type ALOXE3 enables structure-function studies. The knockout is valuable for studying epidermal lipid biology, hepoxilin signaling, and ichthyosis disease mechanisms.

Yes. ALOXE3 rescue experiments are well-established for epidermal lipid research: • Construct design: use a codon-modified ALOXE3 sequence with a small C-terminal tag (FLAG, HA). ALOXE3 has the lipoxygenase architecture but with atypical (lacking standard dioxygenase) activity — preserve protein integrity. • Catalytically-dead rescue: active site iron-binding mutations abolish hepoxilin synthase activity. • ARCI patient mutation rescue: patient-derived ALOXE3 mutations enable disease modeling. • Functional readout: rescue should restore hepoxilin A3 generation from 12R-HPETE substrate. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying ANGPT2 (angiopoietin-2)'s role as the principal Tie2 ligand antagonist or modeling angiogenesis and emerging anti-angiogenic therapy. The Knockout line is the standard tool for asking whether ANGPT2 is required for these processes — ANGPT2 is a secreted growth factor that binds Tie2 (TEK) receptor on endothelial cells with similar affinity to ANGPT1 but functions as a context-dependent agonist/antagonist; ANGPT2 destabilizes endothelial junctions, promotes vascular remodeling, and is critical for pathological angiogenesis in cancer and diabetic retinopathy/age-related macular degeneration (AMD). Overexpression is useful for studying ANGPT2 gain-of-function effects. For angiogenesis and vascular biology research, the EDITGENE ANGPT2 Knockout in HEK293 is uniquely valuable — HEK293 supports systematic structure-function studies. Rescue with wild-type ANGPT2 is the standard specificity control. The knockout is a critical specificity tool for ⭐⭐ faricimab (Vabysmo, FDA-approved 2022, anti-Ang2 × anti-VEGF bispecific antibody for neovascular AMD and diabetic macular edema), ⭐ nesvacumab (anti-Ang2 antibody), trebananib (Ang1/2-binding peptibody), and emerging Ang2-Tie2 axis-targeted therapeutics in cancer and retinal vascular diseases — Ang2 has emerged as a key target alongside VEGF for retinal vascular diseases.

Yes. ANGPT2 rescue experiments require attention to secreted growth factor architecture: • Construct design: use a codon-modified ANGPT2 sequence with a small N-terminal tag (FLAG, HA, after signal peptide). ANGPT2 has signal peptide, coiled-coil oligomerization domain, and C-terminal fibrinogen-like Tie2-binding domain — preserve all elements. • Secretion validation: confirm conditioned media ANGPT2 secretion by ELISA. • Tie2-binding-deficient rescue: fibrinogen-like domain mutations disrupt Tie2 binding. • Functional readout: rescue should restore ANGPT2-induced Tie2 destabilization and faricimab binding. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying ALPL (tissue-nonspecific alkaline phosphatase, TNAP)'s role as the principal regulator of extracellular pyrophosphate or modeling hypophosphatasia (HPP). The Knockout line is the standard tool for asking whether ALPL is required for these processes — ALPL is the tissue-nonspecific alkaline phosphatase isoform (versus tissue-specific intestinal, placental, germ cell isoforms) expressed in bone, liver, kidney, and other tissues; ALPL hydrolyzes inorganic pyrophosphate (PPi) into inorganic phosphate, promoting bone mineralization (PPi is an inhibitor of hydroxyapatite formation); ALPL also dephosphorylates pyridoxal-5'-phosphate, LPS, and other substrates. Overexpression is useful for studying ALPL gain-of-function effects. For skeletal disease research, the EDITGENE ALPL Knockout in HEK293 is uniquely valuable — ALPL biallelic loss-of-function mutations cause hypophosphatasia (HPP), a rare metabolic bone disease with spectrum of presentations from perinatal lethal to adult dental forms. Rescue with wild-type or patient-derived ALPL mutations enables disease modeling. The knockout is a critical specificity tool for ⭐ asfotase alfa (Strensiq, FDA-approved enzyme replacement therapy for perinatal/infantile/juvenile-onset HPP), and emerging ALPL-targeted therapeutics.